News
Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in ...
COPD, or chronic obstructive pulmonary disease, affects more than 30 million Americans, yet many have never heard of it. COPD ...
Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...
3d
Stars Insider on MSNWhat is chronic obstructive pulmonary disease?According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...
4d
Onlymyhealth on MSNChronic Disease Awareness Day 2025: Expert Shares Early Signs You Should Not IgnoreIf you’ve been brushing off persistent fatigue frequent headaches or unexplained weight changes your body might be telling ...
Verona Pharma’s flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...
A recent national study revealed ongoing symptom burden and communication gaps in COPD care, and provided physicians with actionable improvement strategies.
6d
MedPage Today on MSNManaging Weight in COPDDietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.
5d
Clinical Trials Arena on MSNFirst subject dosed in Upstream Bio’s Phase II trial of verekitug for COPDUpstream Bio has dosed the first subject in the Phase II trial of verekitug in individuals with chronic obstructive pulmonary disease (COPD).
The Canadian Press on MSN15h
How to read Environment Canada's air quality index and find out if you're at riskWildfire season is upon us once again, and smoke is reducing air quality through swaths of the country. Environment Canada ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results